This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Greatbatch, Inc. Reports 2013 Second Quarter Results

Greatbatch, Inc. (NYSE: GB), today announced results for its second quarter ended June 28, 2013 highlighted by 6% constant currency organic revenue growth, 19% improvement in adjusted operating income and 30% improvement in adjusted diluted EPS over the prior year. Additionally, the Company raised its full year adjusted diluted EPS guidance to $2.05 - $2.15 per share.
Three Months Ended
(Dollars in thousands, except per share data) June 28,     June 29,     %     March 29,   %
2013 2012 Change 2013 Change
Sales $ 171,331 $ 166,548 3% $ 148,265 16%
Constant Currency Organic Sales Growth 6% 1% -4%
GAAP Operating Income $ 17,135 $ 11,091 54% $ 14,339 19%
GAAP Operating Income as % of Sales 10.0% 6.7% 9.7%
Adjusted Operating Income* $ 22,192 $ 18,589 19% $ 19,311 15%
Adjusted Operating Income as % of Sales 13.0% 11.2% 13.0%
GAAP Diluted EPS $ 0.39 $ 0.16 144% $ 0.23 70%
Adjusted Diluted EPS* $ 0.56 $ 0.43 30% $ 0.44 27%
Adjusted EBITDA* $ 31,281 $ 28,518 10% $ 28,075 11%
Adjusted EBITDA as a % Sales 18.3% 17.1% 18.9%
* Refer to Tables A, B and C at the end of this release for a reconciliation of GAAP to adjusted amounts.
  • Sales increased 3% over the second quarter of 2012 to a record $171.3 million, including 6% constant currency organic growth.
    • Cardiac/neuromodulation revenue increased 5% driven by stronger market performance and continued deepening relations with OEM partners.
    • Orthopaedic revenue decreased 2% over the prior year but grew organically by 14% due to implant market share gains and new customer wins, after adjusting for the divestiture of certain non-core product lines in Switzerland at the beginning of 2013.
    • Portable medical revenues increased 9% for the quarter reflecting the ongoing impact of products introduced in 2012.
  • GAAP Operating Income of $17.1 million increased $6.0 million or 54% in the quarter.
    • Gross margins improved 220 basis points to 33.4% driven by plant productivity, the completion of the Swiss orthopaedic facility consolidation and mix of product sales.
    • Total operating expenses declined $0.7 million or 2% as a result of lower other operating expenses reflecting lower consolidation and optimization charges, partially offset by higher selling, general and administrative spend because of continued investment in our sales and marketing capabilities.
  • Adjusted Operating Income improved 19% to $22.2 million.
    • Gross profit improvement and operational efficiencies flowed through to adjusted operating income.

CEO Comments

“We are very pleased with our performance in the second quarter, which reflected 6% constant currency organic revenue growth and a 30% increase in adjusted diluted earnings per share,” stated Thomas J. Hook, President and CEO, Greatbatch, Inc. “Additionally, during the quarter we took steps to realign our operating structure in order to further facilitate our growth strategy.”

1 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.55 0.59%
FB $102.72 3.20%
GOOG $693.99 2.30%
TSLA $148.19 -0.04%
YHOO $27.60 2.90%


Chart of I:DJI
DOW 16,059.13 +44.75 0.28%
S&P 500 1,874.25 +22.04 1.19%
NASDAQ 4,351.5520 +82.7890 1.94%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs